By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Therion Biologics Corporation 

76 Rogers Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-475-7500 Fax: 617-475-7501




Company News
Therion Biologics Corporation Reports Results Of Phase 3 PANVAC-VF Trial And Announces Plans For Company Sale 6/28/2006 12:40:11 PM
Therion Biologics Corporation Reports Results Of Phase 2 PROSTVAC(R)-VF Trial At American Society of Clinical Oncology Annual Meeting And Formalizes Plan For An National Cancer Institute-Sponsored Phase 3 Study 6/5/2006 10:19:22 AM
Therion Biologics Corporation Announces Conclusion Of PANVAC-VF Phase 3 Trial 6/1/2006 11:12:27 AM
Therion Biologics Corporation Completes Phase III Enrollment For PANVAC-VF Pancreatic Cancer Trial; BLA Planned For 2006 2/10/2006 10:15:58 AM
Therion Biologics Corporation Secures $50 Million To Complete Pivotal Clinical Development Program 12/27/2005 10:40:58 AM
Therion Biologics Corporation To Present At Mass Opportunities Biotechnology Investment Conference10/19/2005 5:12:00 PM
Therion Biologics Corporation Establishes Clinical Advisory Board To Guide The Development Of Its Multiple Therapeutic Cancer Vaccine Programs10/19/2005 5:11:56 PM
Therion Biologics Corporation To Present At Biotechnology Industry Organization (BIO) Emerging Company Investor Forum10/19/2005 5:11:49 PM
Researchers Present Results From Studies Of Therion Biologics Corporation's Therapeutic Cancer Vaccines In Patients With Pancreatic Cancer10/19/2005 5:11:38 PM
Therion Biologics Corporation Receives FDA Agreement To Initiate Phase III Clinical Trial With PANVA10/19/2005 5:11:28 PM